首页> 美国卫生研究院文献>The Oncologist >Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)

【2h】

Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)

机译：晚期肝细胞癌患者的连续舒尼替尼治疗：瑞士临床癌症研究小组（SAKK）和瑞士肝脏研究协会（SASL）多中心II期试验（SAKK 77/06）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background.Sunitinib (SU) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity. The objective of this trial was to demonstrate antitumor activity of continuous SU treatment in patients with hepatocellular carcinoma (HCC).

机译：背景：舒尼替尼（SU）是一种具有抗肿瘤和抗血管生成活性的多靶点酪氨酸激酶抑制剂。该试验的目的是证明持续SU治疗肝细胞癌（HCC）患者的抗肿瘤活性。

著录项

期刊名称 The Oncologist
作者
Dieter Koeberle; Michael Montemurro; Panagiotis Samaras; Pietro Majno; Mathew Simcock; Andreas Limacher; Stefanie Lerch; Katalin Kovàcs; Roman Inauen; Vivianne Hess; Piercarlo Saletti; Markus Borner; Arnaud Roth; György Bodoky;
展开▼
作者单位

展开▼
年(卷),期 2010(15),3
年度 2010
页码 285–292
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Hepatocellular carcinoma Sunitinib Tyrosine kinase inhibitor RECIST;

机译：肝细胞癌;舒尼替尼;酪氨酸激酶抑制剂;RECIST;

相似文献

外文文献
中文文献

1. Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06) [J] . Andreas Limacher, Arnaud Roth, Dieter Koeberle, The oncologist . 2010,第3期

机译：晚期肝细胞癌患者的持续舒尼替尼治疗：瑞士临床癌症研究小组（SAKK）和瑞士肝脏研究协会（SASL）多中心II期试验（SAKK 77/06）
2. 6515 Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): A multicenter phase II trial (SAKK 77/06 and SASL 23) [J] . D.Koeberle, M.Montemurro, P.Samaras, European Journal of Cancer Supplements . 2009,第2期

机译：6515不可治愈的肝细胞癌（HCC）患者持续舒尼替尼治疗：一项多中心II期试验（SAKK 77/06和SASL 23）
3. 6515 Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): A multicenter phase II trial (SAKK 77/06 and SASL 23) [J] . D.Koeberle, M.Montemurro, P.Samaras, European Journal of Cancer Supplements . 2009,第2期

机译：6515不可治愈的肝细胞癌（HCC）患者持续舒尼替尼治疗：一项多中心II期试验（SAKK 77/06和SASL 23）
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
6. External beam radiotherapy for unresectable hepatocellular carcinoma an international multicenter phase I trial SAKK 77/07 and SASL 26 [O] . Evelyn Herrmann, Diana Naehrig, Manfred Sassowsky, 2017

机译：一项国际多中心I期临床试验SARK 77/07和SASL 26用于无法切除的肝细胞癌的外部束放射疗法
7. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06) [O] . Koeberle, Dieter, Montemurro, Michael, Samaras, Panagiotis, 2010

机译：晚期肝细胞癌患者的持续舒尼替尼治疗：瑞士临床癌症研究小组（SAKK）和瑞士肝病研究协会（SASL）多中心II期试验（SAKK 77/06）

Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)

摘要

著录项

相似文献

相关主题

期刊订阅